HUTCHMED (00013) to Present Clinical Data at 2025 European Society for Medical Oncology (ESMO) Annual Conference

Stock News

2025/10/02

HUTCHMED (00013) announced that the company will present the latest and updated data from multiple studies of its proprietary compounds at the European Society for Medical Oncology 2025 Annual Conference, scheduled to take place from October 17-21, 2025, in Berlin, Germany.

The registrational FRUSICA-2 study results evaluating fruquintinib in combination with sintilimab as second-line therapy for locally advanced or metastatic renal cell carcinoma will be presented during the mini oral presentation session. Additionally, further analytical results from the FRUSICA-1 study investigating fruquintinib for endometrial cancer treatment, as well as the SACHI and SAVANNAH studies examining savolitinib for non-small cell lung cancer treatment, will be showcased in the poster presentation sessions.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1155672705"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155672705\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155672705?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-02 08:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155672705","market":"sh","top_or_hot":-1,"title":"HUTCHMED (00013) to Present Clinical Data at 2025 European Society for Medical Oncology (ESMO) Annual Conference","media":"Stock News","content":"<p>HUTCHMED (00013) announced that the company will present the latest and updated data from multiple studies of its proprietary compounds at the European Society for Medical Oncology 2025 Annual Conference, scheduled to take place from October 17-21, 2025, in Berlin, Germany.</p>\n<p>The registrational FRUSICA-2 study results evaluating fruquintinib in combination with sintilimab as second-line therapy for locally advanced or metastatic renal cell carcinoma will be presented during the mini oral presentation session. Additionally, further analytical results from the FRUSICA-1 study investigating fruquintinib for endometrial cancer treatment, as well as the SACHI and SAVANNAH studies examining savolitinib for non-small cell lung cancer treatment, will be showcased in the poster presentation sessions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED (00013) to Present Clinical Data at 2025 European Society for Medical Oncology (ESMO) Annual Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED (00013) to Present Clinical Data at 2025 European Society for Medical Oncology (ESMO) Annual Conference\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-10-02 08:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>HUTCHMED (00013) announced that the company will present the latest and updated data from multiple studies of its proprietary compounds at the European Society for Medical Oncology 2025 Annual Conference, scheduled to take place from October 17-21, 2025, in Berlin, Germany.</p>\n<p>The registrational FRUSICA-2 study results evaluating fruquintinib in combination with sintilimab as second-line therapy for locally advanced or metastatic renal cell carcinoma will be presented during the mini oral presentation session. Additionally, further analytical results from the FRUSICA-1 study investigating fruquintinib for endometrial cancer treatment, as well as the SACHI and SAVANNAH studies examining savolitinib for non-small cell lung cancer treatment, will be showcased in the poster presentation sessions.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"","article_id":"1155672705","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155672705","pubTimestamp":1759363822,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HUTCHMED (00013) announced that the company will present the latest and updated data from multiple studies of its proprietary compounds at the European Society for Medical Oncology 2025 Annual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK1191":"制药","BK4588":"碎股","BK1588":"回港中概股","BK1587":"次新股","BK4585":"ETF&股票定投概念","00013":"和黄医药","HCM":"和黄医药","BK4531":"中概回港概念"},"translate_title":"和黄医药(00013)将在2025年欧洲肿瘤内科学会(ESMO)年会上展示临床数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCM":1,"00013":1},"content_text":"HUTCHMED (00013) announced that the company will present the latest and updated data from multiple studies of its proprietary compounds at the European Society for Medical Oncology 2025 Annual Conference, scheduled to take place from October 17-21, 2025, in Berlin, Germany.\nThe registrational FRUSICA-2 study results evaluating fruquintinib in combination with sintilimab as second-line therapy for locally advanced or metastatic renal cell carcinoma will be presented during the mini oral presentation session. Additionally, further analytical results from the FRUSICA-1 study investigating fruquintinib for endometrial cancer treatment, as well as the SACHI and SAVANNAH studies examining savolitinib for non-small cell lung cancer treatment, will be showcased in the poster presentation sessions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}